Nycomed Strikes $70 Mil. Deal To Develop Acusphere’s AI-700 In Europe
This article was originally published in The Gray Sheet
Executive Summary
Nycomed will seek European regulatory approval for Acusphere's AI-700 ultrasound contrast agent as part of a co-development and distribution deal signed between the two concerns July 7
You may also be interested in...
Acusphere Goes Public, NDA In Sight For Myocardial Perfusion Imaging Agent
Acusphere expects to file a new drug application for its AI-700 enhanced ultrasound contrast agent no later than 2005
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.